RBM47

Across TCGA pan-cancer cohorts, RBM47 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RBM47 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher RBM47 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated RBM47 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where RBM47 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	III,IV	0.870	0.537	.005	36	view →
LUAD	OS	Median	II,III,IV	1.000	0.862	.004	34	view →
PDAC	DFS	Median	All	0.384	0.195	.001	25	view →
COAD	DFS	Median	III,IV	1.000	0.844	.044	12	view →
GBM	OS	Median	All	0.268	0.483	.013	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RBM47–CCRCC (OS)

Open the CCRCC breakdown →